Back to search results

Safety of REGN7508 and REGN9933 for Atrial Fibrillation

This study is looking at two experimental drugs, REGN7508 and REGN9933, for adults with atrial fibrillation (AF), a condition where the heart beats too fast and unevenly. These drugs are designed to help prevent blood clots. The study aims to compare the bleeding effects of REGN7508 and REGN9933 to a commonly used medication called apixaban. You may be able to join if you are an adult with AF or flutter (a similar heart rhythm problem) and need ongoing blood clot prevention. The main goal is to see how often any bleeding occurs in participants over 12 weeks. The study is currently recruiting about 1200 participants.

Study design
This is an interventional study involving approximately 1200 participants. It compares the effects of REGN7508 and REGN9933 with apixaban.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint measures bleeding incidence at 12 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07175428

Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Recruiting
PHASE2Ages 18+InterventionalPrevention
Regeneron Pharmaceuticals
~1,200 participants
Updated 2026-09-15 on ClinicalTrials.gov
What's tested:REGN7508REGN9933Apixaban

At a glance

Recruiting sites
80 of 81 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of any bleeding
Measured over 12 weeks

Conditions

Atrial Fibrillation (AF)

Explore related trials

Atrial Fibrillation

NCT07175428

Where you'd take part

This study runs at 81 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • AA Medical Research Center (MRC)

    Flint, Michiganno site contact published

    Recruiting

  • Advanced Medical Research

    Maumee, Ohiono site contact published

    Recruiting

  • Alpine Research TC

    Clinton, Utahno site contact published

    Recruiting

  • Anderson Medical Research

    Ft. Washington, Marylandno site contact published

    Recruiting

  • Beth Israel Lahey Health, Beth Israel Deaconess Medical Center (BIDMC)

    Boston, Massachusettsno site contact published

    Recruiting

  • Blue Coast Research Center, LLC

    Indianapolis, Indianano site contact published

    Recruiting

  • Cardiologia Assistencial e de Pesquisa Ltda (Cardresearch)

    Belo Horizonte, Minas Gerais, Brazilno site contact published

    Recruiting

  • Cardiology Associates Medical Group

    Ventura, Californiano site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Clinical Trial Management · STUDY_DIRECTOR · Regeneron Pharmaceuticals

Who to contact

Clinical Trials Administrator
[email protected]
844-734-6643
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of any bleeding12 weeks

    Defined as the composite of International Society on Thrombosis and Haemostasis (ISTH) major bleeding, ISTH Clinically Relevant Non-Major (CRNM) bleeding, or minor bleeding